Digital Wavefront Sensing

Reproducibility and Comparison of Digital Wavefront Sensing With Conventional Shack-Hartmann Wavefront Sensing: an Explorative Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04597255

Acronym

DWS

Enrollment

Registered

2020-10-22

Start date

2020-12-31

Completion date

2021-12-31

Last updated

2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors, Wavefront Aberration, Corneal

Keywords

digital wavefront sensing, optical coherence tomography

Brief summary

A holographic optical coherence tomography (H-OCT) setup is used to detect the wavefront by means of phase reconstruction.

Detailed description

H-OCT will be tested in this study for its suitability for the qualitative investigation of aberrometry. We aim to achieve a digital equivalent for wavefront calculation of the widespread analog procedure commonly used with conventional wavefront-aberrometers. The results will be compared with those from a conventional analog wavefront calculation method. In the course of this pilot study, 20 eyes of phakic and 10 eyes of pseudophakic subjects with suspected higher order aberrations will be examined using H-OCT.

Interventions

DEVICEHolographic optical coherence tomography

Descriptive wavefront analysis with holographic optical coherence tomography

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

1. Informed consent 2. Men and women aged between 18 and 85 years 3. Normal ophthalmic findings except refractive errors or suspected higher order aberrations 4. Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant

Exclusion criteria

1. Hyperopia \> +6 Dpt. and Myopia \< -6 Dpt. 2. Known ophthalmic diseases such as age related macular degeneration, diabetic retinopathy, glaucoma, retinal detachment or previous ocular trauma and surgeries except cataract extraction 3. Participation in a clinical trial in the previous 3 weeks 4. Presence of any abnormalities preventing reliable measurements as judged by the investigator 5. Pregnancy, planned pregnancy or lactating

Design outcomes

Primary

Measure	Time frame	Description
Qualitative description of lower order aberrations (LOA)	14 +/- 3 days	Zernike terms, RMS-error, Strehl ratio
Qualitative description of higher order aberrations (HOA)	14 +/- 3 days	Zernike terms, root mean square error , Strehl ratio

Contacts

Primary ContactDoreen Schmidl, MD, PhD

klin-pharmakologie@meduniwien.ac.at40400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026